ERBB2 and cancer: After the NeoSphere and TRYPHAENA study were published in 2012 and 2013, showing that dual antibody blockade with trastuzumab and pertuzumab in the neoadjuvant setting led to improved disease-free survival in early-stage HER2+ cancers, the rate of NAT increased.8–10 The response to NAT gives valuable prognostic information, as pCR is associated with better recurrence-free and overall survival.22 This allows clinicians to optimize adjuvant treatment in accordance with risk category.